Pacira BioSciences' Other Non-Current Liabilities rose 32.09% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year increase of 32.09%. This contributed to the annual value of $20.2 million for FY2024, which is 18.05% down from last year.
According to the latest figures from Q3 2025, Pacira BioSciences' Other Non-Current Liabilities is $25.3 million, which was up 0.60% from $25.2 million recorded in Q2 2025.
Pacira BioSciences' 5-year Other Non-Current Liabilities high stood at $57.6 million for Q4 2021, and its period low was $11.1 million during Q3 2021.
Its 3-year average for Other Non-Current Liabilities is $24.3 million, with a median of $23.9 million in 2025.
Data for Pacira BioSciences' Other Non-Current Liabilities shows a peak YoY increase of 357.52% (in 2022) and a maximum YoY decrease of 51.18% (in 2022) over the last 5 years.
Pacira BioSciences' Other Non-Current Liabilities (Quarterly) stood at $57.6 million in 2021, then slumped by 51.18% to $28.1 million in 2022, then dropped by 12.18% to $24.7 million in 2023, then dropped by 18.05% to $20.2 million in 2024, then soared by 32.09% to $25.3 million in 2025.
Its last three reported values are $25.3 million in Q3 2025, $25.2 million for Q2 2025, and $23.9 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value